After obtaining all the regulatory approvals, Bal Pharma Ltd's bulk drugs manufacturing unit at Udaipur has commenced its commercial production of intermediates and Active Pharma Ingredients (API).
The API products which of scheduled to be manufactured at this Unit were developed by our R&D facility at Bangalore and due to capacity constraints at our Bangalore facility they could not become commercially viable till now.
This unit is expected to ease the capacity concerns of API's and intermediates and will cater to the North are Northeastern markets of the country and also overseas markets.
To recapitulate, we have acquired 100% share holding and management control of Golden Drugs Pvt Ltd, Udaipur, Rajasthan, during March 2018, which is into manufacturing of API's and intermediates during March 2018.
Shares of BAL PHARMA LTD. was last trading in BSE at Rs.79.7 as compared to the previous close of Rs. 81.1. The total number of shares traded during the day was 7321 in over 121 trades.
The stock hit an intraday high of Rs. 83.7 and intraday low of 79.3. The net turnover during the day was Rs. 595214.